Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 4 Aug 2026

Grade 1 NET and PRRT: When Lu-177 DOTATATE Can Wait

If your GEP-NET is Grade 1 and your disease is stable, PRRT with lutetium Lu-177 dotatate may not be the right next step yet. Learn what the evidence says about timing PRRT for low-grade neuroendocrine tumors - and when a Grade 1 NET does cross the threshold for treatment.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 4 Aug 2026
Grade 1 NET and PRRT: When Lu-177 DOTATATE Can Wait

This article is for patients following the DOTATATE track with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). If you have a Grade 1 (G1) NET and wonder whether lutetium Lu-177 dotatate - the radioactive compound used in PRRT (peptide receptor radionuclide therapy) - should be your next step, this article will help you work through that question. Grade 1 is the slowest-growing category of neuroendocrine tumor. Your grade alone does not decide whether you need PRRT right now, even though PRRT can work very well for the right patient.

The short answer: A Grade 1 GEP-NET with a Ki-67 index under 3 percent usually does not require PRRT right away. Standard eligibility for PRRT includes documented disease progression and confirmed somatostatin receptor uptake on a Ga-68 DOTATATE PET scan. If your tumor is stable on a somatostatin analogue, evidence supports continuing that approach before moving to Lu-177 dotatate.

What Grade 1 Means on Your Pathology Report

When your NET biopsy is assessed, your pathologist assigns a grade based on how fast your tumor cells are dividing. The main measure is the Ki-67 index - a percentage showing what fraction of tumor cells are actively multiplying at the time of the biopsy.

Under the WHO classification for gastroenteropancreatic neuroendocrine neoplasms, the grades break down as follows:

  • Grade 1 (G1): Ki-67 less than 3 percent
  • Grade 2 (G2): Ki-67 between 3 and 20 percent
  • Grade 3 (G3): Ki-67 above 20 percent in a well-differentiated tumor
  • Neuroendocrine carcinoma (NEC): Poorly differentiated and high-grade - a separate, more aggressive category with different treatment pathways

A Ki-67 below 3 percent means tumor cells are dividing very slowly. This is what doctors call a slow-growing or indolent tumor. Many patients with metastatic G1 NETs live with their diagnosis for years - sometimes over a decade - while on medical care alone, without needing an intensive treatment like PRRT.

For a closer look at how pathology grading shapes your treatment plan, the article What Your NET Pathology Grade Means for PRRT Eligibility covers the grading system and what different Ki-67 results mean for your options.

Why PRRT Eligibility Is About More Than Your Grade

A common assumption is that a Grade 1 diagnosis either automatically qualifies you for PRRT or automatically rules it out. Neither is accurate.

PRRT delivers radiation to tumor cells that have somatostatin receptors on their surface. Lutetium Lu-177 dotatate is a radioactive compound that binds to those receptors and kills the cells holding them. If your tumor has high receptor expression, the treatment can deliver a meaningful dose directly to the cancer. If receptor expression is low or missing, the treatment has little to target and won't work.

This is why the essential first step in PRRT evaluation is a Ga-68 DOTATATE PET scan - a nuclear imaging test that maps somatostatin receptor expression across your body. It tells your medical team how targetable your tumor is right now. The article How Ga-68 DOTATATE PET Determines Your PRRT Eligibility explains what the scan measures and what the result means for your case.

Beyond receptor status, standard PRRT eligibility also typically requires documented disease progression on imaging, adequate kidney function, adequate bone marrow reserve, and sufficient overall health to complete a multi-cycle treatment course. Grade 1 alone does not satisfy these criteria. Most G1 patients haven't shown documented progression yet - their tumors are still stable.

Somatostatin Analogues Come First in Most G1 Cases

For most G1 GEP-NET patients, the established first line of medical therapy is a class of medications called somatostatin analogues (SSAs). These drugs act like a natural hormone that slows cell growth, bind to the same somatostatin receptors that PRRT targets, slow tumor growth, and can control hormonal symptoms such as diarrhea and flushing. They can stabilize disease for months or years.

A review based on the CLARINET study showed that the SSA lanreotide significantly delayed progression in well-differentiated, non-progressive NETs, including G1 tumors. Patients with stable low-grade disease got real benefit from SSA therapy alone, without needing to escalate to PRRT.

Equally important: the NETTER-1 trial - the large phase 3 study that established lutetium Lu-177 dotatate as an effective treatment for midgut NETs - specifically enrolled patients whose tumors progressed despite somatostatin analogue therapy. Patients had to show their SSA wasn't working to join the study. The main evidence supporting PRRT comes from patients who had already progressed on an SSA - not from those with stable G1 disease on current therapy.

In practice: if your SSA is controlling your tumor, there is limited trial evidence to support moving to PRRT instead of continuing that therapy. Your oncologist will generally want to see clear, documented progression before recommending the switch.

When a G1 NET Likely Does Not Need PRRT Right Now

You may not be at the point of needing PRRT if any of the following describes your situation:

  • Stable scans over 12 to 14 months. If your CT or MRI scans from a year apart show no meaningful growth, your tumor isn't growing by standard measures. As the American Cancer Society notes, active surveillance is a recognized approach for slow-growing, low-grade NETs.
  • No prior trial of SSA therapy. Moving directly to PRRT without first trying a somatostatin analogue bypasses a well-supported first-line option. Most NET guidelines recommend SSAs before moving to PRRT in the G1 setting.
  • Low overall tumor burden. Very small or limited G1 tumors - particularly those found by chance in the pancreas - may pose a low immediate risk. The potential long-term effects of PRRT on kidney function and bone marrow might matter more than the benefit when the tumor is causing few problems today.
  • Weak somatostatin receptor signal on PET. A Ga-68 DOTATATE PET showing low or absent uptake means there is little for Lu-177 dotatate to target. Having a Grade 1 tumor can't make up for a weak receptor signal - PRRT is unlikely to help in this setting.

When a Grade 1 NET May Be Ready for PRRT

Even at Grade 1, some patients do reach the point where PRRT is the right next step. The clinical signals that commonly support moving toward PRRT include: documented progression on serial imaging while on an SSA; new metastatic lesions appearing on follow-up scans; worsening symptoms no longer adequately controlled by current therapy; strong somatostatin receptor uptake on Ga-68 DOTATATE PET; and kidney and bone marrow function within acceptable ranges for treatment.

A 2025 review of PRRT in Grade 1 and 2 GEP-NETs supports the use of PRRT in progressive G1 patients, with generally favorable outcomes given the well-differentiated biology of these tumors. The review also shows that most available clinical data comes from patients who had already progressed on SSAs - consistent with how most NET specialists sequence treatment today.

If your current therapy appears to be losing its effect, the article Lu-177 DOTATATE vs Somatostatin Analogues for GEP-NETs: When to Switch Therapies covers the clinical markers your oncologist will look for before recommending a change.

A Biology Note: G1 Tumors Often Have High Receptor Expression

One reason G1 NET patients can be strong eventual candidates for PRRT is the biology of their tumors. Well-differentiated cells tend to preserve somatostatin receptor expression. SSTR2A receptor expression is typically highest in G1 and G2 tumors compared to high-grade or poorly differentiated disease. This matters because when a G1 patient eventually progresses and becomes eligible for PRRT, their Ga-68 DOTATATE PET scan is often strongly positive - and high tumor uptake is generally associated with a better PRRT response. Timing PRRT carefully in G1 disease means preserving an effective option for when it's truly needed and most likely to work.

When a Second Opinion Is Worth Seeking

NET treatment is specialized, especially the question of when to start PRRT for slow-growing tumors. Not every oncologist managing NET patients has deep experience with current sequencing guidelines. If you are unsure why you are being advised to wait, or if PRRT has been offered without a clear discussion of what progression criteria were met, a second opinion from an experienced NET specialist team is worth pursuing.

A thorough evaluation should include a nuclear medicine physician who reads Ga-68 DOTATATE PET scans, a NET-specialist oncologist or endocrinologist, and a review of your serial scan data to assess how your disease is changing. If you would like your pathology and imaging reviewed by a team with specific GEP-NET experience, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you - and what alternatives exist if not.

Living with a G1 NET While You Wait

Being told that PRRT is not yet the right step is not easy to hear - especially if you have spent time researching the treatment and were hoping it was available to you now. Living with a cancer diagnosis combined with a watchful waiting plan is stressful. Disrupted sleep and persistent worry about what the next scan will show are common experiences among NET patients in this phase. These concerns deserve attention alongside your clinical care.

If sleep disruption and anxiety are affecting your daily life during this period, discussing them with your care team is a good first step. For over-the-counter supportive options in the meantime, Ayurnomics's Sleep and Stress range includes Ayurvedic products that some patients find helpful during periods of uncertainty - not as a cancer treatment, but as help with daily life while dealing with your diagnosis.

Staying on your regular scan schedule, continuing SSA therapy as prescribed, and maintaining follow-up appointments with your NET specialist gives you the monitoring structure to catch any meaningful change in how your disease is progressing early. If progression appears on your next set of scans, the conversation about PRRT can move forward from there.

When to Talk to Your Doctor

Bring up PRRT timing with your oncologist or NET specialist if any of the following applies:

  • Your most recent scan shows growth compared to a previous scan
  • New lesions have appeared since your last imaging
  • Your current therapy is no longer controlling your symptoms well
  • You have not yet had a Ga-68 DOTATATE PET scan to assess your receptor status
  • You feel uncertain whether your current management plan reflects current NET guidelines

You can submit your Ga-68 DOTATATE PET report and pathology for a dedicated eligibility review through the Lutetium Therapy contact form. If PRRT is not yet the right fit, the team can advise on what criteria would need to change - and whether alternative options are worth discussing in the meantime.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Can a Grade 1 NET patient ever qualify for PRRT?

Yes. Grade 1 does not rule out PRRT. Most G1 patients simply are not at the stage where PRRT is the right next step yet, because their disease has not progressed beyond what a somatostatin analogue can control. When a G1 NET shows documented progression on imaging and the Ga-68 DOTATATE PET confirms strong receptor uptake, PRRT may be an appropriate and effective option. G1 tumors also tend to have high somatostatin receptor expression, which is a favorable predictor of PRRT response.

How do I know if my G1 NET is progressing?

Progression is determined by comparing serial imaging scans - usually CT or MRI - taken several months apart. Your oncologist looks for measurable increases in tumor size or the appearance of new lesions. A Ga-68 DOTATATE PET scan may also be used to assess changes in receptor-active tumor volume. Most treatment protocols require documented progression within the 12 to 14 months preceding PRRT to confirm active disease growth before starting treatment.

What is the difference between a Grade 1 NET and a neuroendocrine carcinoma?

Grade 1 NETs are well-differentiated tumors with a Ki-67 index below 3 percent. They grow slowly and generally carry more treatment options and a longer natural history. Neuroendocrine carcinomas (NECs) are poorly differentiated, high-grade tumors that behave more aggressively. NECs are classified separately and are generally not suitable for PRRT because they tend to have low or absent somatostatin receptor expression. Confirming your exact diagnosis on pathology - including Ki-67 and differentiation status - is essential before discussing PRRT.

If I have a Grade 1 NET with liver metastases, does that change when I need PRRT?

The presence of liver metastases increases tumor burden and can raise the urgency of treatment decisions. However, the core question remains whether the disease is progressing on imaging. A stable G1 NET with liver involvement may still be appropriately managed with a somatostatin analogue, with PRRT considered when progression is confirmed. Your eligibility will also depend on whether your liver function is adequate to support treatment. A dedicated eligibility review will factor in your liver involvement alongside all other criteria.

Is it possible to lose PRRT eligibility by waiting too long with a G1 NET?

This is less common in G1 patients than in higher-grade disease, but it is worth monitoring for. The main risks from extended waiting are grade transformation (a tumor shifting to a higher Ki-67 over time), declining somatostatin receptor expression on repeat PET imaging, or changes in kidney or bone marrow function that could affect treatment tolerance. Regular follow-up scans and periodic check-ins with your NET specialist are the safest way to stay eligible for PRRT should you need it.

What should I bring to my appointment to discuss PRRT timing for a G1 NET?

Bring copies of all recent imaging reports and scan discs (CT, MRI, Ga-68 DOTATATE PET if you have had one), your pathology report with the Ki-67 index clearly noted, your current medication list including any somatostatin analogues, and recent blood test results covering kidney function, liver function, and a full blood count. If you have been seen at more than one center, consolidating records from all sites into one place before your appointment will help your specialist assess your disease trajectory and give you a clear answer on timing.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Grade 1 NET and PRRT: When to Wait on Lu-177 DOTATATE | lutetium-therapy